Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.

Benjamin BenzonStephanie A GlavarisBrian W SimonsRobert M HughesKamyar GhabiliPatrick MullaneRebecca MillerKatriana NugentBrian ShinderJeffrey TosoianEphraim J FuchsPhuoc T TranPaula J HurleyMilena Vuica-RossEdward M SchaefferCharles G DrakeAshley E Ross

Published in: Prostate cancer and prostatic diseases (2018)

Trimodal therapy consisting of androgen deprivation, cryoablation and PD-1 blockade, as well as the combination of cryoablation and low dose anti-CTLA-4 blockade showed that local therapies with cryoablation could be considered to augment the effects of checkpoint blockade in prostate cancer.

Keyphrases

prostate cancer
low dose
radical prostatectomy
dna damage
stem cells
bone marrow
cell therapy